SAXOL

Taxane-based chemotherapies are among the most frequently used cancer therapies. However, they have adverse effects such as neuropathy (CIPN), which have a major impact on patients' quality of life. These neuropathies are often the cause of treatment discontinuation and compromise the success of the cancer treatment. In 1 out of 4 cases, they may even persist irremediably.

SAXOL project is based on the discovery of Carba1, which acts in synergy with Taxol®, allowing doses to be reduced while maintaining its therapeutic effectiveness. It also activates a metabolic enzyme, which has a neuroprotective effect.

• Reduction of taxane doses for a preserved therapeutic effect: limitation of toxicities due to taxane formulations, reduction of resistance.

• Neuroprotective effect preventing the onset of neuropathies for which there is no effective preventive treatment.

• Validated and patented method for the synthesis of Carba1
• Synergistic effect of the Carba1/Taxol combination validated in vivo in a mouse tumour model
• ADME-Tox: performed, no warning signals
  
• Neuroprotection: demonstrated on neurons in vitro. Target and mechanism of action known.

• Cancer chemotherapy
• Prevention of chemo-induced peripheral neuropathy
• Potential prevention of other neuropathies (diabetes) and neurodegenerative diseases